Bronchial wall necrosis secondary to mucormycosis following SARS-Cov2 infection: A case report

Arjmand, Ghazal; Askari, Elham; Kazemi, Arya; Zarei, Ehsan; Haseli, Sara; Sadraei, Nazanin

doi:10.1016/j.radcr.2022.05.049

Cited by 1 publication

(1 citation statement)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The SARS-CoV-2 infection is characterized by a wide spectrum of clinical complications. A recent case report showed that a diabetic patient recovering from SARS-CoV-2 infection was followed by endobronchial necrosis as a result of pulmonary mucormycosis infection, which was confirmed by histopathological examinations and computed tomography [ 59 ]. Another study showed that four patients aged more than 42 years were administered with steroids, and half of them had comorbidities of pulmonary mucormycosis and SARS-CoV-2, in which computed tomography revealed pulmonary cavitation and empyema [ 60 ].…”

Section: Mucormycosis and Sars-cov-2 Comorbiditymentioning

confidence: 99%

An Attention towards the Prophylactic and Therapeutic Options of Phytochemicals for SARS-CoV-2: A Molecular Insight

et al. 2023

View full text Add to dashboard Cite

The novel pathogenic virus was discovered in Wuhan, China (December 2019), and quickly spread throughout the world. Further analysis revealed that the pathogenic strain of virus was corona but it was distinct from other coronavirus strains, and thus it was renamed 2019-nCoV or SARS-CoV-2. This coronavirus shares many characteristics with other coronaviruses, including SARS-CoV and MERS-CoV. The clinical manifestations raised in the form of a cytokine storm trigger a complicated spectrum of pathophysiological changes that include cardiovascular, kidney, and liver problems. The lack of an effective treatment strategy has imposed a health and socio-economic burden. Even though the mortality rate of patients with this disease is lower, since it is judged to be the most contagious, it is considered more lethal. Globally, the researchers are continuously engaged to develop and identify possible preventive and therapeutic regimens for the management of disease. Notably, to combat SARS-CoV-2, various vaccine types have been developed and are currently being tested in clinical trials; these have also been used as a health emergency during a pandemic. Despite this, many old antiviral and other drugs (such as chloroquine/hydroxychloroquine, corticosteroids, and so on) are still used in various countries as emergency medicine. Plant-based products have been reported to be safe as alternative options for several infectious and non-infectious diseases, as many of them showed chemopreventive and chemotherapeutic effects in the case of tuberculosis, cancer, malaria, diabetes, cardiac problems, and others. Therefore, plant-derived products may play crucial roles in improving health for a variety of ailments by providing a variety of effective cures. Due to current therapeutic repurposing efforts against this newly discovered virus, we attempted to outline many plant-based compounds in this review to aid in the fight against SARS-CoV-2.

show abstract

Section: Mucormycosis and Sars-cov-2 Comorbiditymentioning

confidence: 99%